Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets: 2015-2024

Historic Non-Current Assets for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $121.8 million.

  • Syndax Pharmaceuticals' Non-Current Assets rose 99.62% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 99.62%. This contributed to the annual value of $121.8 million for FY2024, which is 280.45% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Non-Current Assets of $121.8 million as of FY2024, which was up 280.45% from $32.0 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Non-Current Assets ranged from a high of $121.8 million in FY2024 and a low of $1.3 million during FY2021.
  • For the 3-year period, Syndax Pharmaceuticals' Non-Current Assets averaged around $53.7 million, with its median value being $32.0 million (2023).
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Non-Current Assets declined by 27.90% in 2021, and later surged by 490.80% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Non-Current Assets (Yearly) stood at $1.7 million in 2020, then decreased by 27.90% to $1.3 million in 2021, then spiked by 490.80% to $7.5 million in 2022, then skyrocketed by 329.58% to $32.0 million in 2023, then skyrocketed by 280.45% to $121.8 million in 2024.